The haemodynamic effects of iodinated water soluble radiographic contrast media: a review

European Journal of Radiology
Sameh K MorcosJ O Karlsson


All classes of iodinated water-soluble radiographic contrast media (RCM) are vasoactive with the iso-osmolar dimers inducing the least changes in the vascular tone. The mechanisms responsible for RCM-induced changes in the vascular tone are not fully understood and could be multifactorial. A direct effect on the vascular smooth muscle cells causing alterations in the ion exchanges across the cell membrane is thought to be an important factor in RCM-induced vasodilatation. The release of the endogenous vasoactive mediators adenosine and endothelin may also play a crucial role in the haemodynamic effects of RCM particularly in the kidney. In addition, the effects of RCM on blood rheology can cause a reduction in the blood flow in the microcirculation. The purpose of this review is to discuss the pathophysiology of the haemodynamic effects of RCM and to offer some insight into the biology of the endothelium and vascular smooth muscle cells as well as the pharmacology of the important vasoactive mediators endothelin and adenosine.


Jul 1, 1992·Journal of the American Society of Nephrology : JASN·S N HeymanF H Epstein
Nov 1, 1992·The British Journal of Radiology·P BrownA M el Nahas
Nov 1, 1992·The British Journal of Radiology·N Gomi
Jan 1, 1992·Annual Review of Physiology·T Maack
Jan 1, 1992·The Journal of Antimicrobial Chemotherapy·S N HeymanM Brezis
Nov 11, 1991·Journal of the American Society of Nephrology : JASN·K B MarguliesJ C Burnett
Oct 1, 1991·Investigative Radiology·M GardinaliA Agostoni
Jan 1, 1991·The British Journal of Radiology·J L HaylorS K Morcos
Mar 1, 1991·American Journal of Respiratory Cell and Molecular Biology·S M Albelda
Apr 1, 1991·Radiology·J D Pearson
May 1, 1991·The British Journal of Radiology·A A el SayedS K Morcos
Jan 1, 1990·Annual Review of Pharmacology and Toxicology·L Birnbaumer
Jul 5, 1990·The New England Journal of Medicine·J R VaneR M Botting
Dec 1, 1990·Kidney International·K B MarguliesJ C Burnett
Nov 1, 1990·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·L Birnbaumer
Jan 1, 1987·Journal of Cardiovascular Pharmacology·T Ashida, M P Blaustein
May 1, 1989·Cardiovascular and Interventional Radiology·D M Morgan, M A Bettmann
Sep 5, 1989·The American Journal of Cardiology·P Dawson
Jan 1, 1987·Drugs·K L Axelsson, J Ahlner
Nov 1, 1988·Australasian Radiology·F J Palmer
Oct 1, 1987·AJR. American Journal of Roentgenology·R H Cohan, N R Dunnick
Apr 1, 1988·The British Journal of Radiology·J K HaldH Stormorken
Oct 1, 1987·Nature·T M GriffithK T Evans
Oct 1, 1986·The British Journal of Radiology·P Dawson, M Howell
Nov 1, 1985·Investigative Radiology·P De MaeyerJ Vermylen

❮ Previous
Next ❯


Jun 22, 2005·European Radiology·Sameh K MorcosUNKNOWN Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)
Jan 6, 2006·European Radiology·Peter AspelinUNKNOWN Members of the Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR)
Jun 9, 2007·Pharmacy World & Science : PWS·Frank Ga JansmanJohannes W Harting
Jan 24, 2012·European Heart Journal·Erdmann SeeligerPontus B Persson
Apr 8, 2014·BioMed Research International·Erdmann SeeligerPontus B Persson
Oct 23, 2012·Vascular Pharmacology·Egeria ScodittiMaria Rosa Montinari
Dec 4, 2015·Nuklearmedizin. Nuclear Medicine·Soo J KimByung-Tae Kim
May 24, 2003·The British Journal of Radiology·S K Morcos
Feb 6, 1999·European Journal of Radiology·S K MorcosJ O Karlsson
May 23, 2017·Journal of Stomatology, Oral and Maxillofacial Surgery·R GryseleynJ Ferri
Apr 15, 2004·Clinical Radiology·S K Morcos
Mar 5, 2019·Clinical Nuclear Medicine·Thomas S C NgHeather A Jacene
Mar 9, 2006·Journal of the American College of Nutrition·Stephen A Hoption Cann
Aug 13, 2020·Thyroid : Official Journal of the American Thyroid Association·Cristina Maldonado-AraqueGemma Rojo-Martínez
Dec 24, 2002·Investigative Radiology·Werner Krause, Matthias Schromm

❮ Previous
Next ❯

Related Concepts

Related Feeds


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.


Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.